Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia.

Détails

ID Serval
serval:BIB_67C18F8C2B74
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia.
Périodique
Heart rhythm
Auteur⸱e⸱s
Krug D., Blanck O., Andratschke N., Guckenberger M., Jumeau R., Mehrhof F., Boda-Heggemann J., Seidensaal K., Dunst J., Pruvot E., Scholz E., Saguner A.M., Rudic B., Boldt L.H., Bonnemeier H.
ISSN
1556-3871 (Electronic)
ISSN-L
1547-5271
Statut éditorial
Publié
Date de publication
12/2021
Peer-reviewed
Oui
Volume
18
Numéro
12
Pages
2137-2145
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Ventricular tachycardia (VT) is a potentially lethal complication of structural heart disease. Despite optimal management, a subgroup of patients continue to suffer from recurrent VT. Recently, cardiac stereotactic body radiotherapy (CSBRT) has been introduced as a treatment option in patients with VT refractory to antiarrhythmic drugs and catheter ablation.
The purpose of this study was to establish an expert consensus regarding the conduct and use of CSBRT for refractory VT.
We conducted a modified Delphi process. Thirteen experts from institutions from Germany and Switzerland participated in the modified Delphi process. Statements regarding the following topics were generated: treatment setting, institutional expertise and technical requirements, patient selection, target volume definition, and monitoring during and after CSBRT. Agreement was rated on a 5-point Likert scale. The strength of agreement was classified as strong agreement (≥80%), moderate agreement (≥66%) or no agreement (<66%).
There was strong agreement regarding the experimental status of the procedure and the preference for treatment in clinical trials. CSBRT should be conducted at specialized centers with a strong expertise in the management of patients with ventricular arrhythmias and in stereotactic body radiotherapy for moving targets. CSBRT should be restricted to patients with refractory VT with optimal antiarrhythmic medication who underwent prior catheter ablation or have contraindications. Target volume delineation for CSBRT is complex. Therefore, interdisciplinary processes that should include cardiology/electrophysiology and radiation oncology as well as medical physics, radiology, and nuclear medicine are needed. Optimal follow-up is required.
Prospective trials and pooled registries are needed to gain further insight into this promising treatment option for patients with refractory VT.
Mots-clé
Anti-Arrhythmia Agents/adverse effects, Anti-Arrhythmia Agents/therapeutic use, Catheter Ablation/adverse effects, Consensus, Contraindications, Procedure, Delphi Technique, Drug Resistance, Heart Diseases/complications, Heart Diseases/pathology, Humans, Patient Selection, Radiosurgery/methods, Tachycardia, Ventricular/etiology, Tachycardia, Ventricular/therapy, Electrical storm, Radioablation, Stereotactic radiotherapy, Structural heart disease, Ventricular tachycardia
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/08/2021 13:09
Dernière modification de la notice
16/03/2022 7:32
Données d'usage